Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Shi, Qingyang; Nong, Kailei; Olav Vandvik, Per; Guyatt, Gordon; Schnell, Oliver; Rydén, Lars; Marx, Nikolaus; C. Brosius, Frank; A. Mustafa, Reem; Agarwal, Arnav; Zou, Xinyu; Mao, Yunhe; Asadollahifar, Aminreza; Rahman Chowdhury, Saifur; Zhai, Chunjuan; Gupta, Sana; Gao, Ya; Pedro Lima, João; Numata, Kenji; Qiao, Zhi; Fan, Qinlin; Yang, Qinbo; Jin, Yinghui; Ge, Long; Yang, Qiuyu; Zhu, Hongfei; Yang, Fan; Chen, Zhe; Lü, Xi; He, Siyu; Chen, Xiangyang; Lyu, Xiafei; An, Xingxing; Chen, Yaolong; Hao, Qiukui; Standl, Eberhard; Siemieniuk, Reed; Agoritsas, Thomas; Tian, Haoming; Li, Sheyu

doi:10.1136/bmj-2022-074068

Public

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Published in BMJ • Apr 6, 2023

Authors:

Qingyang Shi

Kailei Nong

Per Olav Vandvik

Abstract

OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agon...

Subject

Medicine

Type 2 diabetes

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!